Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease

Status Recruiting

Clinical Trial Summary

STUDY OBJECTIVES Primary: To assess the safety and tolerability of ischemia-tolerant allogeneic human mesenchymal stem cells (hMSCs) manufactured by Stemedica versus placebo administered intravenously to subjects with mild to moderate dementia due to Alzheimer's disease. Secondary: To assess the preliminary efficacy of hMSCs versus placebo in subjects with Alzheimer's-related dementia, as evidenced by neurologic, functional, and psychiatric endpoints.

Clinical Trial Description

This is a Phase IIa multi-center, randomized, single-blind, placebo-controlled, crossover study in subjects with mild to moderate dementia due to Alzheimer's disease. Only the subject and their caregiver will be blinded to the study treatment. The study will consist of two cohorts of subjects (20 subjects per cohort), randomized in a 1:1 allocation to receive active study drug or placebo. Cohort 1 will receive a single intravenous dose of hMSCs of 1.5 million cells per kilogram body weight on their Study Day 1, and Cohort 2 will receive equal volume of Lactated Ringer's Solution on their Study Day 1. At the six-month time point for each subject after their first infusion, Cohort 1 will receive a single intravenous dose of Lactated Ringer's Solution and Cohort 2 will receive a single intravenous dose of hMSCs at 1.5 million cells per kilogram of the subject's body weight. Approximately 40 subjects will be enrolled in this study. An independent Data and Safety Monitoring Board will conduct periodic safety reviews. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02833792
Study type	Interventional
Source	Stemedica Cell Technologies, Inc.
Contact	Lev Verkh, PhD
Phone	858-658-0910
Email	lverkh@stemedica.com
Status	Recruiting
Phase	Phase 2
Start date	June 1, 2016
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03255720` - Application of Diffusion Tensor Imaging in Alzheimer's Disease :Quantification of White Matter Micro-structural Changes	N/A
Recruiting	`NCT03507192` - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.	N/A
Withdrawn	`NCT05497817` - A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia	N/A
Completed	`NCT02317523` - Alzheimer's Caregiver Coping: Mental and Physical Health	N/A
Completed	`NCT03538522` - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831	Phase 2
Terminated	`NCT03132272` - Immunoadsorption for Treatment of Alzheimer's Disease	N/A
Recruiting	`NCT03275363` - The University of Hong Kong Neurocognitive Disorder Cohort	N/A
Enrolling by invitation	`NCT03724136` - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study	N/A
Completed	`NCT02267486` - Exploratory Study for the Validity of QuQu Scale	N/A
Active, not recruiting	`NCT03748303` - Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study	Phase 1
Completed	`NCT03611439` - Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients	N/A
Completed	`NCT04058886` - Telephone-delivered Mindfulness Intervention for African American Dementia Caregivers	N/A
Recruiting	`NCT03584568` - Reappraising Intergeneration Relationships in Dementia Caregiving	N/A
Not yet recruiting	`NCT05113732` - Association of Cognition With Functional Mobility in People With Alzheimer's Disease
Completed	`NCT03811847` - A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.	Phase 4
Terminated	`NCT03044249` - A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression	Phase 2
Active, not recruiting	`NCT03661034` - Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)	N/A
Completed	`NCT03718494` - Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)
Completed	`NCT03602391` - The Senior Companion Program Plus	N/A
Completed	`NCT03548584` - A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type	Phase 3